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ABSTRACT
Thalassemia is an inherited disorder of autosomal recessive gene caused by decrease 
or absent production of one or two type of globin chain. This disorder will affect the 
quality and quantity of blood production. In Indonesia, thalassemia is not concerned as 
urgency, although it lies in thalassemia belt area. Thalassemia is classified according 
to the particular globin chain which affected such as a-thalassemia and b-thalassemia. 
Besides thalassemia, there are variant hemoglobinopathy called HbE. The aim of this study 
was to assess the prevalence of thalassemia carriers among the volunteer of screening 
in Yogyakarta Special Region from 2012 until 2015. The thalassemia carrier screening 
was conducted by collaborating with Indonesian Association of Parents of Children with 
Thalassemia (APCT) Yogyakarta. The hematological measurement and High-Performance 
Liquid Chromatography (HPLC) were performed on Prodia Laboratory Yogyakarta. The 
analysis of carriers prevalence was conducted in Laboratory of Genetics and Breeding, 
Faculty of Biology, Universitas Gadjah Mada, Yogyakarta. Among 241 volunteers, we found 
44 volunteers was diagnosed as b-thalassemia carrier, 30 volunteers as a-thalassemia 
carrier as well as HbE disorder carrier, and 1 volunteer was diagnosed as a-b-thalassemia 
carrier. The number of thalassemia carrier shows no significant difference each year. The 
prevalence of thalassemia carrier is high, even though the distribution is limited by the 
location where the screening took place.
ABSTRAK
Thalassemia adalah kelainan bawaan pada gen resesif autosomal akibat penurunan atau 
tidak diproduksinya satu atau dua jenis rantai globin. Kelainan ini mempengaruhi kualitas 
dan kuantitas produksi darah. Di Indonesia, thalasemia belum menjadi masalah penting 
walaupun lokasinya termasuk dalam daerah sabuk thalasemia. Thalasemia diklasifikasikan 
berdasarkan rantai globin yang mengalami mutasi yaitu a-thalasemia dan b-thalasemia. 
Selain thalasemia, ada satu varian hemoglobinopati yang disebut HbE. Tujuan dari 
penelitian ini adalah untuk menentukan prevalensi thalasemia di antara relawan skrining di 
Daerah Istimewa Yogyakarta dari tahun 2012 sampai 2015. Skening thalasemia dilakukan 
dengan bekerjasama Perhimpunan Orang tua Penderita Thalasemia Indonesia (POPTI), 
Daerah Istimewa Yogyakarta. Pemeriksaan hematologi dan High-Performance Liquid 
Chromatography (HPLC) dilakukan di Laboratorum Klinik Prodia, Yogyakarta. Analisis 
prevalensi pembawa gen thalasemia dilakukan di Laboratorium Genetik dan  Pemuliaan, 
Fakultas Biologi, Universitas Gadjah Mada, Yogyakarta. Dari 241 sukarelawan yang 
diskrining, 44 sukarelawan didiagnosis sebagai pembawa a-thalasemia, 30 pembawa 
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b-thalasemia dan HbE serta satu pembawa a-b-thalasemia. Jumlah pembawa thalasemia 
tidak menunjukkan perbedaan yang signifikan setiap tahunnya. Prevalensi pembawa 
thalasemia tinggi, meskipun distribusinya dibatasi oleh lokasi dimana skrining dilakukan.
Keywords: Thalassemia trait screening - a-thalassemia - b-thalassemia – HbE – HPLC
INTRODUCTION
Thalassemia is an inherited disorder 
of autosomal recessive gene caused by 
decrease or absent production of one and/
or two type of globin chain. This disorder 
will affect the quality and quantity of blood 
production.1 Thalassemia is classified 
according to the particular globin chain 
which affected. The α-globin is involved 
in α-thalassemia and theβ-globin chain is 
affected in β-thalassemia.2,3 Approximately 
400 mutations have been reported to cause 
this disorder in the world population.4,5 The 
mutation can cause hereditary anemias due to 
decrease hemoglobin synthesis and red blood 
survival.6 Beside, structural hemolgobin 
variant known as hemoglobinophaty are also 
caused by abnormality in globin chain such as 
HbS, HbC and HbS.7
Previous studies reported that the 
distribution of this disorder were limited to 
the areas called “thalassemia belt” (lies from 
the Mediterranean basin through the Middle 
East and Indian subcontinent up to Southeast 
Asia), but recent migration of people have 
spread thalassemia genes throughout the 
world.6,8 About 7% of the population was 
recorded inherit the disorder throughout Africa 
and Asia.1 In Indonesia, thalassemia is not 
considered as major health problems, although 
it lies in thalassemia belt area. Furthermore, 
thalassemia carrier in Indonesian population 
was recorded and shown high prevalence, 
for detail 3-20% was α-thalassemia carrier, 
3% was β-thalassemia carrier and 1-33% was 
HbE carrier.9
The thalassemia trait which inherits an 
individual only has mutation from one of the 
parents.1 The thalassemia trait does not suffer 
thalassemia, but if the trait marry another trait, 
there would be a chance to have thalassemia 
major disorder or severe anemia.10 Refer to the 
population which reported above, this study 
was conducted to to assess the prevalence of 
thalassemia carriers among the volunteer of 
screening in Yogyakarta Special Region from 
2012 until 2015.
MATERIALS AND METHODS
Volunteers
The material of this research was the 
hematological database as the result of 
screening from Prodia Clinical Laboratory, 
including 241 sheets of cellular medical test 
which contain quantity of cellular blood 
components. Thalassemia screening was 
conducted annually  and collaborated with 
Indonesian Association of Parents of Children 
with Thalassemia (IAPCT) Yogyakarta, the 
Indonesia Thalassemia Foundation (ITF), 
Prodia Clinical Laboratory, Yogyakarta and 
Faculty of Biology Universitas Gadjah Mada, 
Yogyakarta. From 2012 until 2015, there was 
241 volunteers who attended the screening. 
Procedure
Blood collection was conducted in 
Faculty of Biology, Universitas Gadjah 
Mada, Yogyakarta. The hematological 
measurement and High-Performance Liquid 
Chromatography (HPLC) were performed in 
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Prodia Clinical Laboratory, Yogyakarta. To 
define the thalassemia prevalence, the analysis 
was conducted in Laboratory of Genetics and 
Breeding, Faculty of Biology, Universitas 
Gadjah Mada, Yogyakarta. Informed of 
consent was obtained from the volunteer who 
observed. 
Analysis
The data was analyzed using formula of 
Microsoft Excel 2010 due to the assigned 
ranged from Prodia Clinical Laboratory, 
Yogyakarta. The analysis was conducted 
in Laboratory of Genetics and Breeding, 
Faculty of Biology, Universitas Gadjah Mada, 
Yogyakarta.
RESULTS
There were 241 volunteers which 
measured on the thalassemia screening. 
From the screening we found 75 volunteers 
who have thalassemia trait, meaning that 
almost 45% of the volunteer were diagnosed 
disorder. FIGURE 1 shows the prevalence of 
thalassemia among volunteers screened. The 
β-thalassemia trait was recorded most often 
which reached out 44 volunteer, while it was 
founded that α-thalassemia carrier and HbE 
disorder carrier had the same number of 30 
volunteers. However, we found one volunteer 
who had α-β-thalassemia carrier phenotype. 
FIGURE 2 shows that the prevalence for 
female of thalassemia carrier and HbE 
disorder carrier were higher than male.
FIGURE 1. The prevalence of thalassemia among volunteers screened.
FIGURE 2. The prevalence of thalassemia among volunteers screened based on gender
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FIGURE 3 shows the prevalence of 
thalassemia trait in four different years from 
2012 to 2015. The total number of thalassemia 
carrier showed no significant difference from 
2012 to 2015. For α-thalassemia carrier, 
in 2012 the number for volunteer with the 
carrier was lower than β-thalassemia carrier 
(9 volunteers detected). But, different with 
2013, the number of volunteers detected with 
α-thalassemia carrier was the highest among 
other thalassemia carrier (13 volunteers 
detected). In 2014 and 2015, the number of 
α-thalassemia carrier was the lowest among 
others, which were 6 and 2 volunteers 
detected respectively. The number of carrier 
prevalence for β-thalassemia carrier in 2012 
and 2015 was the highest comparing to other 
thalassemia carriers. In 2013, its prevalence 
was the lowest among others, and in 2014, 
number of prevalence for β-thalassemia 
carrier was ranked number two. Also in 2012, 
we obtained a volunteer with α-β-thalassemia 
carrier phenotype. HbE disorder carrier was 
firstly found in 2013 screening with stable 
number in the next year of screening and it 
fluctuated between 9-11 volunteers detected 
with the carrier.
FIGURE 3. The prevalence of thalassemia trait in four different years.
FIGURE 3 shows the distribution of 
thalassemia carrier according to their respective 
native region detected in five provinces, which 
are Yogyakarta Special Region, Central Java, 
East Java, South Sumatra and Riau. Based 
from the screening, the most often thalassemia 
carrier was recorded on province Yogyakarta 
Special Region, followed by Central Java, and 
East Java. In Yogyakarta Special Region and 
Central Java, all of the thalassemia carriers 
were detected.
J Med Sci, Volume 49, No. 3, 2017 July: 106-113
110
FIGURE 4. Distribution of thalassemia trait in five provinces of Indonesia
DISCUSSION
The major study of this research was to 
determine the thalassemia carrier including 
its prevalence and distribution. Thalassemia 
carrier can be found when an individual have 
one or two mutation(s) on a chromosome 
number 11 (α-thalassemia) and one mutation 
on a chromosome number 16 (β-thalassemia). 
In accordance to the diagnostic, we used several 
hematological measurement which were: 
Hemoglobin (Hb), Mean Corpuscular Volume 
(MCV), Mean Corpuscular Hemoglobin 
(MCH), Mean Corpuscular Hemoglobin 
Concentration (MCHC), Hemoglobin AA 
(HbA2) and Hemoglobin F (HbF).11-15 The 
α-thalassemia trait can be diagnosed by the 
low quantity of MCH and MCV.15 With HbA 
reducing and HbA2 and HbF increasing, 
β-thalassemia carrier can be predicted.11-14,16 
On this research, we also determined the HbE 
disorder carrier which had similar phenotype 
with β-thalassemia carrier but had low MCV 
and MCH also the peripheral blood film had 
a normal red cell morphology or minimal 
morphological abnormalities.7,17
Based on FIGURE 1, the prevalence of 
thalassemia carrier was considered high in 
Indonesia. The high prevalence can be caused 
by the gene pool which occurs in some region 
in Indonesia.18,19 In addition, the HbE disorder 
carrier also showed the same trend and recorded 
on every province (FIGURE 4). Furthermore, 
according to gender depicted in FIGURE 
2, the prevalence for female of thalassemia 
carrier and HbE disorder carrier were higher 
than male. Rather than having any kind of 
relevance to each other, thalassemia carrier on 
the other hand is not affected by gender since 
this carrier is inherited as recessive autosomal 
disorder.15 This phenomenon, could be 
happened because there was more female 
than male participant for the whole screening. 
Thus, the probability to thalassemia carrier in 
female was higher than male, as well as shown 
in number of normal volunteers.
On FIGURE 3, thalassemia carrier was 
always found in each year of the screening. 
Total number of thalassemia carrier recorded 
showed no significant difference in each 
year. It was related with thalassemia carrier 
prevalence and distribution. Each thalassemia 
carrier showed different pattern in each years 
of screening. For α-thalassemia, there were 
two forms which diagnosed silent carrier of 
α-thalassemia and α-thalassemia carrier. The 
carrier form mainly has two deleted copies of 
the α-globin gene, whereas the silent carrier 
only lacking one α gene.3 Silent carrier of 
thalassemia has no clinical and hematological 
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phenotype,9 so in this study the carrier which 
analysed only the α-thalassemia carrier. 
The number of the α-thalassemia carrier in 
2012 was lower than β-thalassemia carrier 
which was 9 volunteers. But in 2013, the 
α-thalassemia carrier was the highest number 
for the screening, in which 13 volunteers 
detected with the carrier. In 2014 and 2015, 
the number of α-thalassemia carrier was the 
lowest than others, in which 6 and 2 volunteers 
respectively. 
The β-thalassemia, compared to other 
disorder, was the most common single gene 
disorder found in the world. It results from 
variety of molecular defects that reduce (β+-
thalassemia) or abolish (β0-thalassemia) 
of the β-globin chains of hemoglobin.20 
Inheritance of one β-thalassemia gene results 
in the thalassemia carrier (thalassemia minor), 
inheritance of two defective β-globin genes, 
can result in a wide ranged spectrum of 
clinical conditions depending on the type of 
b-thalassemia mutation (β0 or β+-thalassemia) 
and several other known and uncertain genetic 
factors.21 Number of carrier prevalence for 
β-thalassemia carrier in 2012 and 2015 was 
the highest comparing to other thalassemia 
carriers. In 2014, number of prevalence for 
β-thalassemia carrier was ranked number two 
and in 2013, its prevalence was the lowest 
among others. In 2012, we obtained a volunteer 
with α-β-thalassemia carrier phenotype. The 
α-β-thalassemia carrier is a rare disorder 
because the carrier has a mutation on each 
chromosome (chromosome 11 and 16).16
Furthermore, HbE is the most common 
variant hemoglobinopathies in South East 
Asian.22 It has a nucleotide substitution in 
β-globin chain at codon 26 causing glutamic 
acid substitute into lysine.17 This mutation 
causes a cryptic splice site and makes an 
abnormal mRNA processing. HbE may be 
present in homozygous state, heterozygous 
state, and variety of compound heterozygous 
states such as hemoglobin E/β-thalassemia 
and sickle cell/hemoglobin E disorder.17 
On FIGURE 3, HbE disorder carrier was 
firstly found in 2013 with stable number in 
the next year of screening, it fluctuated in 
9-11 volunteers. The stable number of the 
prevalence may be explained by the specific 
mutation site mentioned above, compared to 
large range mutation of other thalassemia.
As it can be seen, there was a decreasing 
number of α-thalassemia carrier and increasing 
number of β-thalassemia from 2013 to 2015. 
Since the screening was voluntary basis, 
it couldn’t be termed that the prevalence 
pattern was as described from the diagram 
(FIGURE 3). The screening conducted with 
voluntary basis which was before screening 
programes, education session and information 
was provided so attendant were given time to 
provide consent and able to undergo for the 
testing.23-25 This kind of screening was less 
suitable to determine prevalence of disorder 
because the overall screening result is affected 
by the number of volunteers in each year. 
However, from the result at least we can know 
the prevalence and distribution of particular 
disorder from the screening attendant, which 
can be used as basic for recommending 
mandatory screening26 or doing further 
analysis.
On FIGURE 4, we showed that the 
volunteer came from five province in 
Indonesia. The most often thalassemia carrier 
was recorded on province Yogyakarta Special 
Region, followed by Central Java, and East 
Java. This occurrence can be caused by 
the screening location. The screening was 
conducted on the Yogyakarta Special Region. 
However, if we focus on the carrier prevalence, 
the data can be used for determining the 
thalassemia carrier in Indonesia. Similar 
researches have been conducted to determine 
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the prevalence of thalassemia carrier in 
Sumatra Island and Medan city. It was 
reported that more than 7% of the population 
of Palembang, Melayu Sumatra was positively 
β-thalassemia carriers, approximately 20% 
of Sunda Kecil population and 30% of East 
Sumba also positively HbE disorder carrier.18 
The newest research gained in 2008 informed 
that the prevalence of α-thalassemia and 
β-thalassemia in Medan population were 
3.35% and 4.07% respectively.19 This data 
may complete the basis data of thalassemia 
carrier distribution. From the paper, we 
obtained over 241 volunteer, we found 75 
volunteers who had thalassemia carrier. Even 
the distribution is limited by the location where 
the screening took place, we can conclude that 
the prevalence for thalassemia carrier is high.
In addition, Indonesia urgently needed 
more kind of research. There still many 
province and area in Indonesia which 
the thalassemia carrier prevalence and 
distribution remains unknown. Furthermore, 
through this paper we can know whereabouts 
the thalassemia and other hemoglobinopathy 
exist. This used as prevention strategy from 
thalassemia. Before the disorder seriously 
become national problem in Indonesia.
CONCLUSION
From the screening in 2012 until 2015 there 
are 75 volunteers or almost 45% are recorded 
with thalassemia carrier. Most of the disorder 
volunteers are diagnosed with β-thalassemia 
carrier. Total number of thalassemia carrier 
prevalence shows no significant difference 
from 2012 to 2015. The highest number of 
thalassemia carrier prevalence detected in the 
screening from 2012 to 2015 is β-thalassemia, 
α-thalassemia, thalassemia HbE, and 
β-thalassemia carrier respectively. Most of 
thalassemia carrier distribution is recorded 
on Yogyakarta Special Region, followed by 
Central Java and East Java. 
ACKNOWLEDGEMENTS
We would like to thank IAPCT 
Yogyakarta, the ITF, the volunteer on the 
IAPCT Thalassemia Screening 2012 until 
2015 and researchers from Faculty of Biology, 
Universitas Gadjah Mada, Yogyakarta who 
supported the research, specifically thank 
Thalassemia Research Team. We also 
acknowledge Prodia Clinical Laboratory 
Yogyakarta for obtaining samples and 
providing us the hematological data sheets.
REFERENCES
1. Weatherall DJ, Clegg J. The thalassaemia 
syndromes. Oxford: Blackwell Scientific. 
2001; p:289, 422-439. 
2. Weatherall DJ. The Thalassemias. BMJ 1997; 
314(7095):1675-8.
3. Langlois S, Ford JC, Chitayat D, Désilets VA, 
Farrell SA, Geraghty M, et al. Carrier screening 
for thalassemia and hemoglobinopathies 
in Canada. J Obstet Gynaecol Can 2008; 
30(10):950-71.
4. Thein SL. Genetic modifier of beta-
thalassemia. Hematologica 2005; 90(5):649-
60.
5. Moosa MM, Ayub MI, Bashar AE, Sarwardi 
G, Khan W, Khan H, et al. Combination of 
two rare mutations causes β-thalassaemia 
in a Bangladeshi patient. Genet Mol Biol 
2011; 34(3):406-9. http://dx.doi.org/10.1590/
S1415-47572011005000026
6. Ikehara K. Advances in the study of genetic 
disorders. Europe: InTech, 2011; p:101.
7. Fucharoen S, Winichagoon P. Hemo-
globinopathies in Southeast Asia: molecular 
biology and clinical medicine. Hemoglobin 
1997; 21(4):299-319.
113
Nailil Husna et al., Prevalence and distribution of thalassemia trait screening
8. Rahimi Z, Rezaei M, Nagel RL, Muniz 
A. Molecular and hematologic analysis of 
hemoglobin Q-Iran and hemoglobin Setif 
in Iranian families. Arch Iran Med 2008; 
11(4):382-6. http://dx.doi.org/08114/AIM. 
008
9. Viprakasit V, Lee-Lee C, Chong QT, Lin 
KH, Khuhapinant A. Iron chelation therapy 
in the management of thalassemia: the Asian 
perspectives. Int J Hematol 2009; 90(4):435-
45. http://dx.doi.org/10.1007/s12185-009-
0432-0
10. Steinberg M. Disorders of hemoglobin. 
Cambridge: Cambridge University Press, 
2001; p:431-69.
11. Jandl J. Blood. Boston: Little, Brown: 1987.
12. Hoyer JD, Kroft SH. Color atlas of 
hemoglobin disorders, a compendium based 
on proficiency testing. Northfield: College of 
American Pathologists; 2003.
13. Old JM. Screening and genetic diagnosis 
of hemoglobinopathies. Scand J Clin Lab 
Invest 2007; 67(1):71-86. http://dx.doi.
org/10.1080/00365510601046466
14. Galanello R, Origa R. Beta-thalassemia. 
Orphanet J Rare Dis 2010; 5(1):11. http://
dx.doi.org/ 10.1186/1750-1172-5-11
15. Vichinsky EP. Clinical manifestations of 
alpha-thalassemia. Cold Spring Harb Perspect 
Med 2013; 3(5):011742. http://dx.doi.
org/10.1101/cshperspect.a011742
16. Muncie HL Jr, Campbell J. Alpha and beta 
thalassemia. Am Fam Physician 2009; 
80(4):339-44.
17. Bachir D, Galacteros F. Hemoglobin E 
disease. Creteil: Orphanet Encyclopedia, 
2004; p:2-4.
18. Lanni F, Sofro ASM, Ismadi M, Marzuki 
S. ISVI-5 (GÆC): the most common 
β-thalassemia mutation found in the 
Island of Sumatera. Indonesian Journal of 
Biotechnology 2004; 6:571-7.
19. Ganie RA. Distribution of (alpha and beta) 
thalassemia trait and hemoglobin E in 
Medan. Majalah Kedokteran Nusantara 2008; 
41(2):117-22.
20. Angastiniotis M, Modell B. Global 
epidemiology of hemoglobin disorders. 
Annals NY Acad Sci 1998; 850:251-69.
21. Weatherall DJ, Hoffbrand AV, Catovsky 
D, Tuddenham EGD. Hemoglobin and 
inherited disorders of globin chain synthesis 
in postgraduate hematolog 5th edition. New 
Jersey: Blackwell Scientific Publishing, 2005; 
p:85-90.
22. Clarke GM, Higgins TN. Laboratory 
investigation of hemoglobinopathies and 
thalassemias: review and update. Clin Chem 
2000; 46(8 Pt 2):1284-90.
23. Mitchell JJ, Capua A, Clow C, Criver CR. 
Twenty-year outcome analysis of genetic 
screening programs for Tay-Sachs and 
b-thalassemia disease carriers in high schools. 
Am J Hum Genet 1996; 59(4):793-8.
24. Zlotogora J, Carmi R, Lev B, Shalev SA. A 
targeted population carrier screening program 
for severe and frequent genetic diseases in 
Israel. Eur J Hum Genet 2009; 17(5):591-7. 
http://dx.doi.org/10.1038/ejhg.2008.241
25. Cousens NE, Gaff CL, Metcalfe SA, Harper 
MB. Carrier screening for beta-thalassaemia: 
a review of international practice. Eur J Hum 
Genet 2010; 18(10):1077-83. http://dx.doi.
org/10.1038/ejhg.2010.90
26. Alhamdan NA, Almazrou YY, Alswaidi 
FM, Choudhry AJ. Premarital screening for 
thalassemia and sickle cell disease in Saudi 
Arabia. Genet Med 2007: 9(6):372-7. http://
dx.doi.org/10.1097GIM.0b013e318065a9e8
